dolasetron mesylate · Validus Pharms · NDA 020623, 020624
Anzemet
Earliest generic entry, as listed · earliest of 4 marketed strengths
Open now
No marketed reference-listed strength; date taken from all listed strengths.
No unexpired patents or exclusivities are listed for this product.
Listed patents · 0 unexpired
No unexpired patents listed.
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 5
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 020623 · 001 · RLD · discontinued | tablet, oral | 50MG | open |
| 020623 · 002 · RLD · discontinued | tablet, oral | 100MG | open |
| 020624 · 001 · RLD · discontinued | injectable, injection | 100MG/5ML (20MG/ML) | open |
| 020624 · 002 · RLD · discontinued | injectable, injection | 12.5MG/0.625ML (20MG/ML) | open |
| 020624 · 003 · discontinued | injectable, injection | 500MG/25ML (20MG/ML) | open |